Seaport Res Ptn Issues Optimistic Estimate for HIMS Earnings

Hims & Hers Health, Inc. (NYSE:HIMS) – Analysts at Seaport Res Ptn lifted their Q1 2025 EPS estimates for Hims & Hers Health in a note issued to investors on Monday, February 24th. Seaport Res Ptn analyst A. Kessler now anticipates that the company will earn $0.12 per share for the quarter, up from their prior estimate of $0.08. The consensus estimate for Hims & Hers Health’s current full-year earnings is $0.29 per share. Seaport Res Ptn also issued estimates for Hims & Hers Health’s Q2 2025 earnings at $0.15 EPS, Q3 2025 earnings at $0.18 EPS and Q4 2025 earnings at $0.19 EPS.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating the consensus estimate of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to analysts’ expectations of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%.

Other equities analysts have also issued research reports about the company. Morgan Stanley lowered Hims & Hers Health from an “overweight” rating to an “equal weight” rating and upped their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Bank of America increased their target price on shares of Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research note on Thursday, February 20th. TD Cowen reissued a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday, November 20th. Leerink Partners upped their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the stock a “market perform” rating in a report on Tuesday. Finally, BTIG Research assumed coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $33.40.

Hims & Hers Health Stock Performance

Shares of Hims & Hers Health stock opened at $39.95 on Wednesday. The stock has a 50 day moving average of $35.62 and a 200 day moving average of $26.25. The firm has a market capitalization of $8.73 billion, a price-to-earnings ratio of 90.79 and a beta of 1.35. Hims & Hers Health has a fifty-two week low of $9.67 and a fifty-two week high of $72.98.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Crewe Advisors LLC purchased a new position in shares of Hims & Hers Health during the 4th quarter worth approximately $28,000. Raleigh Capital Management Inc. lifted its position in shares of Hims & Hers Health by 1,100.0% in the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after acquiring an additional 1,100 shares in the last quarter. Blume Capital Management Inc. boosted its stake in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Smartleaf Asset Management LLC boosted its position in Hims & Hers Health by 4,415.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the last quarter. Finally, Summit Securities Group LLC acquired a new stake in shares of Hims & Hers Health during the fourth quarter worth $38,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 7,259 shares of Hims & Hers Health stock in a transaction that occurred on Friday, January 10th. The stock was sold at an average price of $24.07, for a total transaction of $174,724.13. Following the transaction, the insider now owns 193,601 shares of the company’s stock, valued at $4,659,976.07. The trade was a 3.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Soleil Boughton sold 4,152 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the completion of the sale, the insider now owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This trade represents a 2.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 1,097,578 shares of company stock valued at $38,080,320 over the last quarter. 17.71% of the stock is owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.